PF-06480605

DRUG3 trials

Sponsors

Telavant, Inc.

Conditions

Colitis, UlcerativeHealthy

Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

CompletedNCT01989143

Telavant, Inc.Healthy

Start: 2013-12-31End: 2015-03-31Updated: 2023-10-19

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

CompletedNCT04269538

Telavant, Inc.Healthy

Start: 2020-02-19End: 2020-11-11Updated: 2023-10-19

Phase 2

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

CompletedNCT02840721

Telavant, Inc.Colitis, Ulcerative

Start: 2016-10-26End: 2018-08-30Updated: 2023-10-23

Related Papers

Japanese Phase 1 Study for Global Development of Anti‐<scp>TL1A</scp> Antibody <scp>PF</scp>‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study

Clinical and Translational Science2025-03-011 citations

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.

2021-06-1261 citations

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

Journal of Crohn s and Colitis2020-01-011 citations

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

Journal of Crohn s and Colitis2020-01-01

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

British Journal of Clinical Pharmacology2019-11-2329 citations